Pliant Pharmaceuticals received notice from Novartis to terminate their Collaboration and License Agreement, resulting in the discontinuation of the development of PLN-1474 for the treatment of liver fibrosis associated with NASH.
AI Assistant
PLIANT THERAPEUTICS INC
2023
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.